Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2025 | $30.00 | Outperform | Leerink Partners |
Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00
8-K - ImageneBio, Inc. (0001835579) (Filer)
424B3 - ImageneBio, Inc. (0001835579) (Filer)
424B3 - ImageneBio, Inc. (0001835579) (Filer)
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " "Company")), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander 37th Annual Healthcare ConferenceFireside Chat: Thursday, December 4, 10:00am ESTNew York, NY To access the live webcasts or subsequent archived recordings of the presentation and f
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory ("I&I") diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio's recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the "Board") and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units ("RSUs") for 153,505 shares of common stock (together, the "Inducement Awards"). The Inducement
3 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
3 - ImageneBio, Inc. (0001835579) (Issuer)